Brenner Robert 4

4 · Vera Therapeutics, Inc. · Filed Feb 6, 2026

AI-generated summary of this filing

Updated Feb 7, 2026

Vera (VERA) CMO Robert Brenner Receives 75,000-Share Award

What Happened

Robert Brenner, Chief Medical Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026: 25,000 shares of Class A common stock and 50,000 restricted stock units (RSUs) reported as a derivative grant. Both were reported at a $0.00 price (i.e., compensation awards), for 75,000 shares/RSUs total. These are grants/awards (transaction code A), not open-market purchases or sales.

Key Details

Transaction date: February 4, 2026. Filing date: February 6, 2026 (filed within the typical 2‑business‑day Form 4 window).
Price: $0.00 per share (compensation grant); total reported value listed as $0 for the acquisition lines.
Vesting/derivative details:
- Footnote F1: The 50,000 RSUs represent shares underlying RSUs that vest one‑fourth on each February 20 in 2027, 2028, 2029 and 2030, subject to continuous service.
- Footnote F3: Separately noted option vesting schedule — 1/48th vests on March 4, 2026 and monthly thereafter, subject to service.
- Footnote F2: Filing also references 624 shares acquired under the company ESPP on March 13, 2025.
Shares owned after transaction: Not specified in the provided filing excerpt.
Filing timeliness: Reported promptly (Feb 6 filing for Feb 4 transactions); not indicated as late.

Context

These are compensation awards, common for executives; RSUs are a derivative grant and do not convert to transferable shares until they vest per the schedule above. Awards at $0 reflect grant accounting, not a market purchase. No sale or exercise occurred in this filing.

Form 4

Period: 2026-02-04

Chief Medical Officer

Transactions

Award
Class A Common Stock
[F1][F2]
2026-02-04+25,000→ 53,098 total
Award
Stock Option (right to buy)
[F3]
2026-02-04+50,000→ 50,000 total
Exercise: $42.74Exp: 2036-02-03→ Class A Common Stock (50,000 underlying)

Footnotes (3)

[F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
[F2]Includes 624 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025.
[F3]1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Signature

/s/ Joseph R. Young, Attorney-in-Fact|2026-02-06

1 file